The significance of p53 mutation and over-expression in ovarian cancer prognosis

International Journal of Gynecological Cancer

Volumn 6, Issue 6, 1996, Pages 483-490

  Allan, L A ^a,f   Campbell, M K ^b   Milner, B J ^a   Eccles, D M ^c   Leonard, R C F ^d   Parkin, D E ^e   Miller, I D ^e   Lessells, A M ^d   Kitchener, H C ^e   Haites, N E ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Wessex Clinical Genetics Service   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

immunohistochemistry; ovarian cancer; p53 tumor suppressor gene; prognosis

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 10144250931     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06060483.x     Document Type: Article

References (26)

1. Marsoni S, Torri V, Valsecchi MG, et al. Prognostic factors in advanced ovarian cancer. Br J Cancer 1990; 62: 444-50.
2. Van der Zee AGJ, Hollema H, Suurmeijer AJH, et al. Value of P-glycoprotein, glutathione s-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-8.
3. 1 phase. Proc Natl Acad Sci USA 1992; 89: 9210-14.
4. Kastan MB, Onyinye O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
5. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9.
6. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosom Cancer 1992; 4: 1-15.
7. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-9.
8. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-55.
9. Yamaguchi A, Kurosaka Y, Fuschida S, et al. Expression of p53 protein in colorectal cancer and its relationship to shortterm prognosis. Cancer 1992; 70: 2778-84.
10. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutation and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993; 53: 1-4.
11. Kurprjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 90: 4961-5.
12. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994; 12: 64-9.
13. Sheridan E, Silcocks P, Smith J, Hancock BW, Goyns MH. p53 mutation in a series of epithelial ovarian cancers from the UK, and its prognostic significance. Eur J Cancer 1994; 30A: 1701-4.
14. Milner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-32.
15. Cannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-602.
16. Banks L, Matlashwski G, Crawford L. Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986; 159: 529-34.
17. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Celli Sci 1992; 101: 183-9.
18. Eccles DM, Brett L, Lessells A, et al. Overexpression of the p53 protein and allelic loss a 17p13 in ovarian carcinoma. Br J Cancer 1992; 65: 40-4.
19. Levesque MA, Katsaros D, Yu H, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995; 75: 1327-38.
20. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979-84.
21. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutations. Oncogene 1992; 7: 743-9.
22. Naito M, Satake M, Sakai E, et al. Detection of p53 gene mutation in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res 1992; 83: 1030-6.
23. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993; 85: 1513-19.
24. Sheridan E, Hancock BW, Goyns MH. High incidence of mutations of the p53 gene detected in ovarian tumours by the use of chemical mismatch cleavage. Cancer Lett 1993; 68: 83-9.
25. Raycroft L, Wu H, Lozano G. Transciptional activation by wild-type but not transforming mutants of the p53 antioncogene. Science 1990; 249: 1049-51.
26. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet 1993; 4: 42-6.